These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

367 related items for PubMed ID: 24614671

  • 21. L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients.
    Schwab N, Schneider-Hohendorf T, Posevitz V, Breuer J, Göbel K, Windhagen S, Brochet B, Vermersch P, Lebrun-Frenay C, Posevitz-Fejfár A, Capra R, Imberti L, Straeten V, Haas J, Wildemann B, Havla J, Kümpfel T, Meinl I, Niessen K, Goelz S, Kleinschnitz C, Warnke C, Buck D, Gold R, Kieseier BC, Meuth SG, Foley J, Chan A, Brassat D, Wiendl H.
    Neurology; 2013 Sep 03; 81(10):865-71. PubMed ID: 23925765
    [Abstract] [Full Text] [Related]

  • 22. A second-generation ELISA (STRATIFY JCV™ DxSelect™) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification.
    Lee P, Plavina T, Castro A, Berman M, Jaiswal D, Rivas S, Schlain B, Subramanyam M.
    J Clin Virol; 2013 Jun 03; 57(2):141-6. PubMed ID: 23465394
    [Abstract] [Full Text] [Related]

  • 23. A benefit-risk analysis of natalizumab in the treatment of patients with multiple sclerosis when considering the risk of progressive multifocal leukoencephalopathy.
    Walker A, Watson C, Alexopoulos ST, Deniz B, Arnold R, Bates D.
    Curr Med Res Opin; 2014 Apr 03; 30(4):629-35. PubMed ID: 24289170
    [Abstract] [Full Text] [Related]

  • 24. Progressive multifocal leukoencephalopathy in two natalizumab-treated stepsisters: An intriguing coincidence.
    Bacchetta F, Mathias A, Schluep M, Du Pasquier R.
    Mult Scler; 2017 Feb 03; 23(2):300-303. PubMed ID: 28165319
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Disease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patients.
    Dahlhaus S, Hoepner R, Chan A, Kleiter I, Adams O, Lukas C, Hellwig K, Gold R.
    J Neurol Neurosurg Psychiatry; 2013 Oct 03; 84(10):1068-74. PubMed ID: 23606731
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Natalizumab-induced PML: can the beast be tamed?
    Hohlfeld R.
    J Neurol Neurosurg Psychiatry; 2013 Oct 03; 84(10):1065. PubMed ID: 23475818
    [No Abstract] [Full Text] [Related]

  • 32. Predictors of severity and functional outcome in natalizumab-associated progressive multifocal leukoencephalopathy.
    Hoepner R, Kolb EM, Dahlhaus S, Hellwig K, Adams O, Kleiter I, Salmen A, Schneider R, Lukas C, Chan A, Berger JR, Gold R.
    Mult Scler; 2017 May 03; 23(6):830-835. PubMed ID: 27600113
    [Abstract] [Full Text] [Related]

  • 33. Immunological biomarkers identifying natalizumab-treated multiple sclerosis patients at risk of progressive multifocal leukoencephalopathy.
    Serana F, Chiarini M, Sottini A, Bertoli D, Giustini V, Tessitore MV, Caimi L, Capra R, Imberti L.
    J Neuroimmunol; 2014 Dec 15; 277(1-2):6-12. PubMed ID: 25468273
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Drug-induced progressive multifocal leukoencephalopathy in multiple sclerosis: European regulators' perspective.
    Anton R, Haas M, Arlett P, Weise M, Balabanov P, Mazzaglia G, Prieto L, Keller-Stanislawski B, Raine J.
    Clin Pharmacol Ther; 2017 Aug 15; 102(2):283-289. PubMed ID: 28001298
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Blood miRNA expression pattern is a possible risk marker for natalizumab-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients.
    Muñoz-Culla M, Irizar H, Castillo-Triviño T, Sáenz-Cuesta M, Sepúlveda L, Lopetegi I, López de Munain A, Olascoaga J, Baranzini SE, Otaegui D.
    Mult Scler; 2014 Dec 15; 20(14):1851-9. PubMed ID: 24852919
    [Abstract] [Full Text] [Related]

  • 39. Design of TRUST, a non-interventional, multicenter, 3-year prospective study investigating an integrated patient management approach in patients with relapsing-remitting multiple sclerosis treated with natalizumab.
    Ziemssen T, Gass A, Wuerfel J, Bayas A, Tackenberg B, Limmroth V, Linker R, Mäurer M, Haas J, Stangel M, Meergans M, Harlin O, Hartung HP.
    BMC Neurol; 2016 Jul 12; 16():98. PubMed ID: 27405225
    [Abstract] [Full Text] [Related]

  • 40. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases.
    Clifford DB, De Luca A, Simpson DM, Arendt G, Giovannoni G, Nath A.
    Lancet Neurol; 2010 Apr 12; 9(4):438-46. PubMed ID: 20298967
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.